Aimed Bio Inc
0009K0
Company Profile
Business description
Aimed Bio Inc is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, especially antibody-drug conjugates (ADC) and bispecific antibodies. It is a next-generation anticancer technology designed to maximize therapeutic efficacy and reduce side effects compared to existing chemotherapeutic agents by selectively delivering anticancer drugs to cancer cells via antibodies. Its product pipelines are AMB302, AMB303, AMB001, and Others.
Contact
67 Jeongui-ro
10th and 11th floors, MK Tower
Songpa-gu
Seoul
KORT: +82 262850743
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
51
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,127.40 | 18.70 | 0.21% |
| CAC 40 | 8,509.64 | 24.00 | 0.28% |
| DAX 40 | 25,629.24 | 17.21 | 0.07% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,868.05 | 29.22 | -0.27% |
| HKSE | 25,916.12 | 31.69 | 0.12% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 63,717.86 | 644.16 | -1.00% |
| NZX 50 Index | 13,744.18 | 44.90 | 0.33% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 8,963.40 | 14.40 | 0.16% |
| SSE Composite Index | 3,809.65 | 22.62 | -0.59% |